[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tourettes-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tourettes-syndrome":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100648797","integrating-exposure-and-response-prevention-and-habit-reversal-techniques-to-treat-a-tourettic-subtype-of-obsessive-compulsive-disorder-tourettic-ocd-100648797",false,"NCT07725926","Integrating Exposure and Response Prevention and Habit Reversal Techniques to Treat a Tourettic Subtype of Obsessive-Compulsive Disorder (Tourettic OCD)","TORCH","Inclusion Criteria:\n\n1. Age 18 years or older\n2. All genders\n3. Confirmation of a primary diagnosis of either:\n\na. Tourettes Disorder \u002F Tourette Syndrome b. Persistent Motor or Vocal Tic Disorder \u002F Chronic Motor or Vocal Tic Disorder c. Provisional Tic Disorder \u002F Transient Motor Tics d. Other Specified Tic Disorder e. Unspecified Tic Disorder f. Obsessive-Compulsive Disorder \\[d\\] Participants taking psychotropic medication are eligible provided medication type and dose remain stable throughout the intervention period \\[e\\] Ability to provide sustained informed consent \\[f\\] A minimum score of 16 on YBOCS \\[g\\] A minimum score of 5 on the Premonitory Urge for Tics Scale (PUTS)\n\nExclusion Criteria:\n\n1. Substance misuse\n2. Current diagnosis of a personality disorder\n3. Schizophrenia\n4. Bipolar disorder\n5. Contraindications to participation in a trial (i.e., active suicidal ideations and\u002For requirement of an interpreter)\n6. Any psychiatric or neurological condition that, in the opinion of the investigators, would interfere with participation or interpretation of study outcomes.","ALL","18 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Obsessive-Compulsive Disorder and Tic Disorders frequently co-occur, and a subgroup of patients - those with a Tourettic Subtype of OCD (TOCD) - present with concurrent obsessive-compulsive and tic symptoms. Existing psychological interventions typically target one condition or the other, but rarely both together. This study aims to test whether a combined psychological therapy integrating Exposure and Response Prevention (ERP) and Habit Reversal (HbRT) is more effective at reducing symptoms than either therapy delivered alone, in adults with TOCD.",[27,28,29,30,31,32,33,34],"Obsessive - Compulsive Disorder","Tic Disorder, Chronic Motor or Vocal","Tic Disorders","Tic Disorder, Combined Vocal and Multiple Motor","Tourette Disease","Tourette Disorder","Tourettes Syndrome","Gilles de la Tourette Syndrome",[36,29,37,38,39,40],"Obsessive-Compulsive Disorder","Tourette Syndrome","Tourettic Obsessive-Compulsive Disorder","Exposure and Response Prevention","Habit Reversal Training","RECRUITING","2026-07-23",{"date":44,"type":45},"2026-07-27","ACTUAL",{"date":47,"type":45},"2026-07-08",{"date":49,"type":21},"2030-02-01",{"name":51,"class":52},"University College London Hospitals","OTHER",2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":65,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":113,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform",true,"2 Years",{"count":64,"type":21},10000,"10 Years","OBSERVATIONAL","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[89,114,115,116,117,118,119,120,121,122,70,123,124,125,126,127,91,128,129,130,131,132,133,134,135],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":138,"type":45},"2026-01-22",{"date":140,"type":45},"2023-07-05",{"date":142,"type":21},"2030-12-31",{"name":144,"class":52},"Brain Inflammation Collaborative",1,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":145},"100543833","exploring-dbs-efficacy-in-treatment-refractory-tourettes-syndrome-100543833","NCT06361004","Exploring DBS Efficacy in Treatment-refractory Tourette's Syndrome","Investigating the Impact of Deep Brain Stimulation (DBS) in Treatment-refractory Tourette's Syndrome (TR-TS)","Inclusion Criteria:\n\n1. aged 18-65;\n2. able to provide written informed consent;\n3. have a diagnosis of Tourette's syndrome according to the Statistical Manual of Mental Disorders-Fourth Edition-Text Revised (DSM-IV-TR) criteria and confirmed by the Mini-International Neuropsychiatric Interview Chinese version 5.0;\n4. with a YGTSS of at least 35 for at least 12 months before surgery, while YGTSS- Total Motor≥15;\n5. must have failed conventional medical treatment at adequate therapeutic doses of three classes of medication lasting for at least three months;\n6. must not be suitable for behavioural intervention or that this intervention is inappropriate or unsuccessful;\n7. have been on stable comorbid conditions without suicidal ideation for at least six months.\n\nExclusion Criteria:\n\n1. presence of other psychotic disorders;\n2. have a treatment history that includes electroconvulsive therapy (ECT), modified electroconvulsive therapy (MECT), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), DBS, and transcranial magnetic stimulation (TMS);\n3. presents a suicide risk (defined as a HAMD-17 score of ≥3 on suicide-related items);\n4. experience difficulty in effectively communicating with investigators;\n5. with a history of traumatic brain injury (TBI);\n6. with intracranial or cardiovascular stents;\n7. substance abuse within the past six months;\n8. unstable neurological or coagulation disorders;\n9. women who are pregnant, lactating, or of childbearing potential who refuse the use of reliable contraception during the study;\n10. have been involved in other clinical studies within three months before enrollment in this study;\n11. any conditions considered by the study group.",{"count":154,"type":21},60,[24],"The primary purpose of this study is to investigate the effect of deep brain stimulation (DBS) in patients with Treatment-refractory Tourette's syndrome (TR-TS) implantation targeting the Antero-medial globus pallidus interna (GPi), Antero-medial globus pallidus interna (amGPi), Postero-ventrolateral GPi (pvGPi), Centromedian nucleus, substantia periventricularis and nucleus ventro-oralis internus (Cm-Spv-Voi), Centre median nucleus and nucleus ventro-oralis (Cm-Voi), or Nucleus Accumbens\u002F Anterior Limb of Internal Capsule (NA-ALIC), or other unreported nuclei targets.",[106],[159],"TS, DBS","NOT_YET_RECRUITING","2024-04-08",{"date":163,"type":45},"2024-04-11",{"date":165,"type":21},"2024-04-20",{"date":167,"type":21},"2029-12-31",{"name":169,"class":52},"Xuanwu Hospital, Beijing"]